Skip To Main Content
Keith Hoffmaster on Muck Rack

Keith Hoffmaster

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Keith Hoffmaster’s profile

Articles by Keith Hoffmaster

An anti-PMEL antibody−drug conjugate with a G q/1 1 inhibitor payload in GNAQ / GNA11 -mutant melanomas: a phase 1 trial

|
By Matteo S. Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, Ryan Sullivan, Richard D Carvajal, Reinhard Dummer, Tanja Gromke, Jessica C Hassel, Damien Kee, Egle Ramelyte, Alexander N. Shoushtari, Alexander Wei, Alexander H. Enk, Heike Richly, Manuel Jorge Rodrigues, Shahneen Sandhu, James W. Smithy, Frank M. Speetjens, Pedro Milanez-Almeida, Anwesha Chaudhury, Mary E. Ising, Javier Otero, Aimee Reynolds, Lillian Werner, Emiliano Calvo, Eleanor E. Handel, Kamaneh Montazeri, Jorge Ramon-Patino, Keith Hoffmaster, Thiruvamoor RamKumar, Sherif Sharaby, Padmaja Yerramilli-Rao
| Nature Verified
Abstract Metastatic uveal melanoma (mUM) is an aggressive cancer with limited treatment options; 85−90% of tumors harbor activating GNAQ and GNA11 mutations. Uveal melanoma cells also express PMEL (also known as PMEL17 or gp100), a melanocyte lineage antigen. DYP688, a novel biology-matched antibody−drug conjugate, binds surface PMEL and delivers the potent Gαq/Gα11 (Gq/11) inhibitor SDZ475 as payload by internalization.
Open in Who Shared Issue with article?
Show More